Clinical Trial

Disease: Solid Tumors, (NCT05395052)

Disease info:

A solid tumour is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Solid tumour types are named according to the type of cell they originate from. Examples of solid tumours are sarcomas, carcinomas, and lymphomas. Leukaemias (cancers of the blood) generally do not form solid tumours. 

The word tumor does not always imply cancer. In discussing tumors that are malignant (cancerous), however, the term solid tumor is used to distinguish between a localized mass of tissue and leukemia.

Frequency:
More than 1.9 million new cancer cases are expected to be diagnosed in the US in 2023.
Official title:
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Who:

Contact

Name: Lilian Liu

Phone: 858-875-1800

Email: clinical@fatetherapeutics.com


Name: Karen Albers

Phone: 858-875-1800

Email: clinical@fatetherapeutics.com

Partners:

-

Locations:

United States, Arizona

Honor Health Research Institute, Scottsdale, Arizona, United States, 85258

 

United States, California

UCLA Division of Hematology-Oncology, Los Angeles, California, United States, 90404

 

United States, New Jersey

Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States, 07601

 

United States, North Carolina

Carolina BioOncology Institute, Huntersville, North Carolina, United States, 28078

 

United States, Texas

NEXT Oncology, San Antonio, Texas, United States, 78229

Study start:
May. 31, 2022
Enrollment:
322
Gene editing method:
CRISPR
Type of edit:
Gene knock-out
Gene:
CD38
Delivery method:
Undisclosed - Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active not recruiting

Description

This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Last updated: Dec. 19, 2023
close
Search CRISPR Medicine